Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Nippon Kayaku Gets Japan Commercial Rights to Anheart’s ROS1 Inhibitor
Nippon Kayaku has obtained the exclusive rights to market and distribute AnHeart Therapeutics’ ROS1 tyrosine kinase inhibitor taletrectinib in Japan for US$40 million upfront. The drug is being developed for the treatment of ROS1-positive non-small cell lung cancer (NSCLC). The…
To read the full story
Related Article
- ROS1 Drug Effective in Japanese Subgroup: Nippon Kayaku
November 5, 2024
BUSINESS
- Japan Approves Fuji’s New Stelara, Simponi Biosimilar Formulations
September 17, 2026
- Maruishi Clinches Japan Rights to Kringle’s Vocal Fold Scar Drug
September 17, 2026
- Nobelpharma, Fuso to Co-Promote Hypozincemia Drug Zintus
September 17, 2026
- Sanofi Japan Targets AI Fluency across Workforce by End-2027
September 16, 2026
- Mounjaro Label Updated with PIII CV Data Showing Noninferiority
September 16, 2026
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…